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Abstract 
Colonic neuroendocrine cell carcinoma (NEC), which is a rare subtype of colon epithelial 
neoplasm, has been reported to show extremely aggressive characteristics with a 1-year 
survival rate of 20%. We report herein a resected case of NEC that manifested bacterial 
sepsis due to sigmoidovesical fistula. Staged surgery consisted of resecting the sigmoid 
colon and part of the bladder four weeks after construction of an ileostomy to alleviate 
septic shock. The resected specimen was histologically diagnosed as NEC invading the 
wall of the urinary bladder with metastasis to the regional lymph nodes. The patient 
underwent four cycles of FOLFOX after surgery for additional treatment of residual 
metastatic lymph nodes around the abdominal aorta diagnosed preoperatively. 
Although the patient showed stable disease measured by computed tomography scan 
for the first three months after surgery, he rejected additional chemotherapy thereafter, 
and died ten months after the initial admission due to progression of residual tumor in 
the urinary bladder as well as the lymph nodes. This is the first case report describing 
colonic NEC manifesting perforation into the urinary bladder. Although the optimal 
chemotherapeutic regimen for colonic NEC has not yet been established, FOLFOX may 
be one of the choices. 
Introduction 
Neuroendocrine cell carcinoma (NEC) of the colon, sometimes described as small cell 
carcinoma of the alimentary tract, is an extremely rare tumor, representing less than 1% 
of colonic cancers [1, 2]. Most patients are diagnosed at an advanced stage, presenting  
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with clinical symptoms and macroscopic characteristics identical to colon 
adenocarcinoma. Because of its highly aggressive biological behavior, it progresses much 
faster than common adenocarcinoma of the colon, with early hemodynamic and 
lymphatic spread leading to a poor prognosis [1, 2]. Although previous reports have 
suggested that tumor resection with subsequent chemo-radiotherapy could be one of the 
favorable treatments, the optimal therapeutic protocol including chemotherapeutic 
regimen has not yet been established [3]. We report a rare case of NEC of the colon with 
sigmoidovesical fistula (SVF). Palliative resection of the tumor followed by chemotherapy 
using the FOLFOX regimen is considered feasible. 
Case Report 
A 78-year-old man was transported by ambulance to our hospital with complaints of severe lower 
abdominal pain, fecaluria and high fever. On admission, his body temperature was 38°C, heart rate was 
more than 100 beats/min, and blood pressure was 75 mm Hg, suggesting septic shock state. Laboratory 
data showed a white blood cell count of 15,100/mm
3 and a C-reactive protein level of 9.5 mg/dl. Urine 
sample contained significant amounts of white blood cells (100 counts/field), red blood cells (50–
99 counts/field) and bacteria (3+), compatible with urinary tract infection. Abdominal computed 
tomography (CT) scan demonstrated a mass lesion at the sigmoid colon with marked inflammatory 
change around the urinary bladder (fig. 1). Bacterial sepsis due to urinary tract infection caused by the 
sigmoid colon tumor penetrating the urinary bladder was highly suspected, although direct visualization 
of SVF was not detected. Emergency surgery including ileostomy for fecal diversion and urethral 
catheterization (triple lumen, 24 French) was performed immediately. The clinical course after 
emergency surgery was good, and staged operation was planned after additional preoperative 
examination. Hypotonic gastrografin enema showed sigmoid colon stenosis without apparent findings 
of SVF. CT scan also showed sigmoid stenosis due to tumor-like mass. Colonoscopy was not performed 
in order to avoid relapse of pyelonephritis by pressure-induced enlargement of the SVF. Serum tumor 
markers, such as carcinoembryonic antigen and carbohydrate antigen 19-9, were within normal limits. 
Based on the diagnosis of sigmoid colon cancer with SVF, the patient underwent the second surgery for 
tumor removal four weeks after the initial surgery. Surgical findings showed a large solid tumor 
invading the bladder wall. Enlarged lymph nodes were found along the inferior mesenteric artery as well 
as the abdominal aorta. Sigmoidectomy with partial resection of the bladder with D2 lymph node 
dissection was carried out. The tumor in the sigmoid colon was 82 × 74 mm in size. Microscopic 
examination demonstrated that the tumor consisted of small round cells with nuclear atypia and had 
directly invaded and penetrated the bladder. Multiple lymph node metastases were also noted. 
Immunohistochemical examination demonstrated that more than 90% of the small cells were positive 
for CD56, which indicated a diagnosis of NEC of the sigmoid colon. The serum biomarker, 
neuronal-specific enolase specific for NEC, showed a high level of 31.9 ng/ml (cut-off level 12 ng/ml) 
even after the second surgery. 
The patient underwent four cycles of chemotherapy intravenously which consisted of 5-fluorouracil 
(2,000 mg/m
2), levofolinate (200 mg/m
2) and oxaliplatin (85 mg/m
2) (FOLFOX regimen). Follow-up CT 
scan three months after the initiation of chemotherapy demonstrated that there was no change in the 
size of paraaortic lymph nodes (fig. 2). However, the patient refused to continue any additional 
treatment. Thereafter, the metastatic lymph nodes and local recurrent tumor grew rapidly and he died 
ten months after the second surgery. 
Discussion 
Colorectal NEC, which has been described as small cell carcinoma in the past, is an 
extremely rare histological type, representing 0.03–0.2% of all colorectal cancers [4, 5]. 
Morphological and biological aggressiveness similar to that of small cell carcinoma of the 
lung is its notable feature. Hung [1] reviewed 39 cases of small cell carcinoma of the colon 
and found that the 1-year survival rate was only 10% with a mean survival time of 
approximately 6 months. Most of the patients were diagnosed at an advanced stage. 
Radical resection at an early stage has been considered the only cure. However, the  
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prognosis of these patients is sometimes dismal even when diagnosed at an early stage. 
Thus, further investigation with regard to its biology as well as therapeutic modality is 
warranted. 
Systemic chemotherapy and/or radiation therapy have been therapeutic alternatives 
especially for advanced NEC, although there are no established standard regimens. 
Thirty-eight cases of advanced colorectal NEC treated with chemotherapy were reviewed 
in our literature survey using the key words ‘neuroendocrine cell carcinoma’, ‘colon’ and 
‘chemotherapy’, to search the MEDLINE database between 1983 and 2008 (table 1) [3, 6–
14].
 We analyzed these 38 cases in addition to our case, and 24 and 15 cases showed liver 
and lymph node metastases. Regarding outcomes, 3 cases achieved complete response 
and 10 cases partial response, and the response rate including complete response, partial 
response and no change was 38%. Concerning the chemotherapeutic regimens, cisplatin 
(CDDP) was administered to 21 cases, and CPT-11 and etoposide were combined in 5 
and 10 cases, respectively. These regimens were considered based on the current regimen 
of small cell carcinoma of the lung.  
Recently several new regimens, such as FOLFOX and/or FOLFIRI, have been reported 
to show more favorable prognoses than conventional regimens for patients with common 
advanced or recurrent colorectal cancers, and the side effects were tolerable. Moreover, as 
the patient’s renal function and digestive function were impaired, CDDP or CPT-11 was 
not indicated for systemic chemotherapy. Therefore, we treated our case using FOLFOX 
and obtained no change for three months without progression of either metastasized 
lymph nodes or local residual tumor. Sunose [15] also reported that liver metastasis 
showed a clinical response to the FOLFOX regimen. Although the results are still 
preliminary, sunitinib has been reported to be clinically effective for neuroendocrine 
cancer of the lung and pancreas [16, 17].
 Combination treatment using chemotherapeutic 
and molecular targeting drugs may achieve a more favorable response. Multicenter 
clinical trials may be an efficient way of elucidating useful regimens especially for this rare 
type of cancer. 
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Table 1. Reported cases of advanced colorectal NEC with metastases and the regimen used for  
chemotherapy and the response to treatment 
Refer-
ence 
Year Lo- 
ca- 
tion 
Site of 
metastasis 
Regimen Re-
sponse
06 2008 C  liver  CDDP+etoposide,  5-FU+CDDP+etoposide  (HAI)  PD 
07 2008 R  LN  CDDP+etoposide,  CPT-11+CDDP  PR 
08  2008  R  local invasion  IFL+radiation (preoperative therapy)  PR 
18  2008  A  liver  5-FU+l-LV (HAI), CPT-11, FOLFOX6  PR 
19 2007 R  local  CDDP+UFT  PD 
20 2007 T  LN,  P  CPT-11  PD 
21 2007 C  liver  CDDP+CPT-11  CR 
      LN, adrenal  CDDP+etoposide, cyclophosphamide+  PR 
      doxorubicin+vincristine   
22 2007 R  LN,  P  IFL  PD 
09  2007  T  liver, LN  hepatectomy+chemotherapy (unknown)  CR 
10 2006 R  liver  CDDP+etoposide  PD 
   S  liver  FOLFIRI,  TACE  PD 
   R  liver,  bone 5-FU+dacarbazine+epirubicin  PD 
    R  liver, lung, LN  CDDP+etoposide  PR 
   C  P  oral  chemotherapy  PR 
   R  liver  xeloda  PR 
15  2006  R  local, liver  CDDP+CPT-11, IFL, FOLFOX4  PR, NC
23 2006 T  liver,  P  CDDP+CPT-11  PD 
24  2006  A  liver, LN  CDDP+5-FU (HAI)  PD 
    D  liver, P  5-FU (HAI), 5-FU+l-LV  PD 
25 2005 R  liver  5-FU,  TS-1  PD 
    R  liver  CDDP+5FU (HAI), FAM+CDDP  PD 
26 2004 R  LN  CDDP+etoposide+paclitaxel  PR 
27 2004 R  liver  CDDP+5-FU  (HAI)+l-LV  PD 
28 2004 T  local  invasion  CDDP+CPT-11  CR 
29  2003  R  liver, LN, local  CDDP+5-FU (HAI)  PD 
11 2002 R  liver,  bone,  skin  unknown  PD 
12  2002  A  liver  vincristin, etoposide, adriamycin, carboplatin, 
taxotere 
PD 
30  2002  R  liver, LN, local, 
bone, skin 
CDDP+etoposide PD 
31 2002 R  LN  CDDP+etoposide  CR 
13 2002 C  LN  unknown  lost  to 
follow-
up 
    D  liver, LN, P  unknown  PD 
02  1999  R  liver, LN, bone  CDDP+5-FU  PR 
14 1999 S  liver,  LN  5-FU+l-LV  PD 
32 1998 R  liver,  local  CDDP+etoposide  PD 
33 1996 A  P  CDDP+etoposide+adriamycin  PD 
34 1996 T  P  CDDP+5-FU  PD 
A = Ascending colon; C = cecum; CDDP = cisplatin; CR = complete response; D = descending colon; 
FAM = 5-fluorouracil+adriamycin+mitomycin; HAI = hepatic arterial infusion; IFL = CPT-11+5-FU+LV; 
LN = lymph node; LV = leucovorin; NC = no change; P = peritoneum; PD = progressive disease; PR = 
partial response; R = rectum; S = sigmoid colon; T = transverse colon; TACE = transcatheter arterial 
chemoembolization.  
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Fig. 1. CT scan demonstrated a mass lesion at the sigmoid colon with marked inflammatory change 
around the urinary bladder. There was an air density lesion in the wall of the bladder (arrow). 
 
 
 
Fig. 2. Follow-up CT scan three months after the initiation of chemotherapy demonstrated no change 
in the size of the paraaortic lymph nodes. a Seven weeks after the first surgery, some paraaortic lymph 
nodes (arrow) demonstrated findings compatible with metastasis. b Three months after the initiation of 
chemotherapy, the size of these lymph nodes had not changed (arrow). 
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